
Opinion|Videos|December 31, 2025
Long-Term Follow-Up Data From ALPINE: Zanubrutinib Vs Ibrutinib in R/R CLL.
Author(s)Marc S. Hoffmann, MD
A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.
Advertisement
The phase 3 ALPINE trial compared the BTK inhibitors zanubrutinib and ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia. In this video, Marc S. Hoffmann, MD, discusses 6-year data from the trial that were presented at the 2025 ASH Annual Meeting. Hoffman highlights efficacy results and discusses optimizing treatment approaches for patients in the R/R setting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































